Distalmotion raises USD 150 million to scale its DEXTER surgical robot in the United States

Distalmotion has raised USD 150 million in Series G financing to accelerate the U.S. expansion of its DEXTER surgical robot.

Vaud-based medtech company Distalmotion has completed a USD 150 million Series G financing round to support the commercial scaling of its DEXTER surgical robot in the United States. The round was led by Revival Healthcare Capital, with participation from existing investors. The new investment follows the company’s recent U.S. regulatory progress, including FDA authorization for gynecological indications, and builds on years of clinical adoption in Europe.

DEXTER is designed to increase access to robotic surgery in outpatient settings by offering a compact, mobile system that integrates into operating rooms without requiring structural modifications. The platform allows surgeons to alternate seamlessly between laparoscopic and robotic modes, and its sterile open console maintains direct visibility of the patient and the surgical team. To date, DEXTER has been used to treat almost 3,000 patients across Europe and the United States.

Financing to accelerate U.S. commercial deployment

The Series G funding will be used to advance U.S. market adoption, with a particular focus on ambulatory surgery centers. These facilities represent one of the fastest growing segments in surgical care due to increasing demand for efficient outpatient procedures. Distalmotion’s earlier FDA approvals and its engagement with U.S. clinicians position DEXTER as a solution designed for high efficiency environments.

In the company’s announcement, CEO Greg Roche described the funding as an important step in Distalmotion’s expansion. He highlighted the continued support of investors and noted that simplified robotic workflows remain central to the company’s mission to broaden access to minimally invasive surgery.

Distalmotion has also strengthened its governance structure with the appointment of Chas McKhann as Executive Chairman of the Board of Directors. Based at the Biopôle life sciences campus in Lausanne, the company will benefit from McKhann’s experience leading publicly traded medtech firms through commercial growth phases.